

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATIONS OF REVENUE BY SEGMENT**  
**EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)**  
(in millions)  
(Unaudited)

| Year-over-Year                              |   |              |                                    |   |  |   |
|---|---|--------------|------------------------------------|---|--|---|
|   | <b>GAAP</b>   |              |                                    |   |  |   |
| <b>GAAP Revenue by Segment</b>              | <b>Q1'24</b>  | <b>Q1'23</b> | <b>Year-over-Year<br/>% Change</b> |   |  |   |
| Life Sciences and Diagnostics Markets Group | \$ 620  | \$ 719       | (14%)                              |   |  |   |
| Agilent CrossLab Group                      | 686   | 652          | 5%                                 |   |  |   |
| Applied Markets Group                       | 352   | 385          | (9%)                               |   |  |   |
| Agilent                                     | \$ 1,658  | \$ 1,756     | (6%)                               |   |  |   |
|   |   |              |                                    |   |  |   |
|   | <b>Non-GAAP<br/>(excluding Acquisitions &amp; Divestitures)</b> |              |                                    | <b>Year-over-Year<br/>at Constant Currency <sup>(a)</sup></b> |  | <b>Current Quarter<br/>Currency Impact <sup>(b)</sup></b> |
| <b>Non GAAP Revenue by Segment</b>          | <b>Q1'24</b>  | <b>Q1'23</b> | <b>Year-over-Year<br/>% Change</b> | <b>Year-over-Year<br/>% Change</b>                            | <b>Percentage Point<br/>Impact from<br/>Currency</b> | <b>Current Quarter<br/>Currency Impact <sup>(b)</sup></b> |
| Life Sciences and Diagnostics Markets Group | \$ 620  | \$ 717       | (14%)                              | (14%)   | —  | \$ 6  |
| Agilent CrossLab Group                      | 686   | 652          | 5%                                 | 4%  | 1 ppt  | 8   |
| Applied Markets Group                       | 352   | 385          | (9%)                               | (9%)  | —  | 2   |
| Agilent (Core)                              | \$ 1,658  | \$ 1,754     | (5%)                               | (6%)  | 1 ppt  | \$ 16   |

We compare the year-over-year change in revenue excluding the effect of acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

<sup>(a)</sup> The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

<sup>(b)</sup> The dollar impact from the quarterly currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATIONS OF REVENUE BY SEGMENT**  
**EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)**  
(in millions)  
(Unaudited)

| Year-over-Year                              |                 |                 |                                |  |  |  |
|---|-----------------|-----------------|--------------------------------|--|--|--|
| <b>GAAP Revenue by Segment</b>              | <b>GAAP</b>     |                 |                                |  |  |  |
|   | <b>Q2'24</b>    | <b>Q2'23</b>    | <b>Year-over-Year % Change</b> |  |  |  |
| Life Sciences and Diagnostics Markets Group | \$ 604          | \$ 726          | (17%)                          |  |  |  |
| Agilent CrossLab Group                      | 664             | 660             | 1%                             |  |  |  |
| Applied Markets Group                       | 305             | 331             | (8%)                           |  |  |  |
| Agilent                                     | <u>\$ 1,573</u> | <u>\$ 1,717</u> | <u>(8%)</u>                    |  |  |  |

  

| <b>Non GAAP Revenue by Segment</b>          | <b>Non-GAAP<br/>(excluding Acquisitions &amp; Divestitures)</b> |                 |                                | <b>Year-over-Year<br/>at Constant Currency <sup>(a)</sup></b> |  | <b>Current Quarter<br/>Currency Impact <sup>(b)</sup></b> |
|---|---|-----------------|--------------------------------|---|--|---|
|   | <b>Q2'24</b>  | <b>Q2'23</b>    | <b>Year-over-Year % Change</b> | <b>Year-over-Year % Change</b>                                | <b>Percentage Point Impact from Currency</b> | <b>Current Quarter Currency Impact <sup>(b)</sup></b>     |
| Life Sciences and Diagnostics Markets Group | \$ 604  | \$ 723          | (17%)                          | (16%)   | -1 ppt                                       | \$ (3)  |
| Agilent CrossLab Group                      | 664   | 660             | 1%                             | 2%  | -1 ppt                                       | (7)   |
| Applied Markets Group                       | 305   | 331             | (8%)                           | (7%)  | -1 ppt                                       | (4)   |
| Agilent (Core)                              | <u>\$ 1,573</u>   | <u>\$ 1,714</u> | <u>(8%)</u>                    | <u>(7%)</u>   | <u>-1 ppt</u>                                | <u>\$ (14)</u>  |

We compare the year-over-year change in revenue excluding the effect of acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

<sup>(a)</sup> The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

<sup>(b)</sup> The dollar impact from the quarterly currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATIONS OF REVENUE BY SEGMENT**  
**EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)**  
(in millions)  
(Unaudited)

| Year-over-Year                              |   |              |                                    |   |  |   |
|---|---|--------------|------------------------------------|---|--|---|
|   | <b>GAAP</b>   |              |                                    |   |  |   |
| <b>GAAP Revenue by Segment</b>              | <b>Q3'24</b>  | <b>Q3'23</b> | <b>Year-over-Year<br/>% Change</b> |   |  |   |
| Life Sciences and Diagnostics Markets Group | \$ 585  | \$ 661       | (11%)                              |   |  |   |
| Agilent CrossLab Group                      | 691   | 672          | 3%                                 |   |  |   |
| Applied Markets Group                       | 302   | 339          | (11%)                              |   |  |   |
| Agilent                                     | \$ 1,578  | \$ 1,672     | (6%)                               |   |  |   |
|   |   |              |                                    |   |  |   |
|   | <b>Non-GAAP<br/>(excluding Acquisitions &amp; Divestitures)</b> |              |                                    | <b>Year-over-Year<br/>at Constant Currency <sup>(a)</sup></b> |  | <b>Current Quarter<br/>Currency Impact <sup>(b)</sup></b> |
| <b>Non GAAP Revenue by Segment</b>          | <b>Q3'24</b>  | <b>Q3'23</b> | <b>Year-over-Year<br/>% Change</b> | <b>Year-over-Year<br/>% Change</b>                            | <b>Percentage Point<br/>Impact from<br/>Currency</b> | <b>Current Quarter<br/>Currency Impact <sup>(b)</sup></b> |
| Life Sciences and Diagnostics Markets Group | \$ 585  | \$ 659       | (11%)                              | (10%)   | -1 ppt   | \$ (5)  |
| Agilent CrossLab Group                      | 691   | 672          | 3%                                 | 4%  | -1 ppt   | (9)   |
| Applied Markets Group                       | 302   | 339          | (11%)                              | (10%)   | -1 ppt   | (4)   |
| Agilent (Core)                              | \$ 1,578  | \$ 1,670     | (5%)                               | (4%)  | -1 ppt   | \$ (18)   |

We compare the year-over-year change in revenue excluding the effect of acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

<sup>(a)</sup> The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

<sup>(b)</sup> The dollar impact from the quarterly currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATIONS OF REVENUE BY SEGMENT**  
**EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)**  
(in millions)  
(Unaudited)

| Year-over-Year                              |                 |                 |                                |  |  |  |
|---|-----------------|-----------------|--------------------------------|--|--|--|
| <b>GAAP Revenue by Segment</b>              | <b>GAAP</b>     |                 |                                |  |  |  |
|   | <b>Q4'24</b>    | <b>Q4'23</b>    | <b>Year-over-Year % Change</b> |  |  |  |
| Life Sciences and Diagnostics Markets Group | \$ 657          | \$ 674          | (3%)                           |  |  |  |
| Agilent CrossLab Group                      | 706             | 672             | 5%                             |  |  |  |
| Applied Markets Group                       | 338             | 342             | (1%)                           |  |  |  |
| Agilent                                     | <u>\$ 1,701</u> | <u>\$ 1,688</u> | 1%                             |  |  |  |

  

| <b>Non GAAP Revenue by Segment</b>          | <b>Non-GAAP<br/>(excluding Acquisitions &amp; Divestitures)</b> |                 |                                | <b>Year-over-Year<br/>at Constant Currency <sup>(a)</sup></b> |  | <b>Current Quarter<br/>Currency Impact <sup>(b)</sup></b> |
|---|---|-----------------|--------------------------------|---|--|---|
|   | <b>Q4'24</b>  | <b>Q4'23</b>    | <b>Year-over-Year % Change</b> | <b>Year-over-Year % Change</b>                                | <b>Percentage Point Impact from Currency</b> | <b>Current Quarter Currency Impact <sup>(b)</sup></b>     |
| Life Sciences and Diagnostics Markets Group | \$ 647  | \$ 674          | (4%)                           | (5%)  | 1 ppt  | \$ 4  |
| Agilent CrossLab Group                      | 706   | 672             | 5%                             | 4%  | 1 ppt  | 4   |
| Applied Markets Group                       | 338   | 342             | (1%)                           | (1%)  | —  | 1   |
| Agilent (Core)                              | <u>\$ 1,691</u>   | <u>\$ 1,688</u> | —                              | —   | —  | <u>\$ 9</u>   |

We compare the year-over-year change in revenue excluding the effect of acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

<sup>(a)</sup> The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

<sup>(b)</sup> The dollar impact from the quarterly currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATIONS OF REVENUE BY SEGMENT**  
**EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)**  
(in millions)  
(Unaudited)

| Year-over-Year                              |                 |                 |                            |  |  |  |
|---|-----------------|-----------------|----------------------------|--|--|--|
| <b>GAAP Revenue by Segment</b>              | GAAP            |                 |                            |  |  |  |
|   | FY24            | FY23            | Year-over-Year<br>% Change |  |  |  |
| Life Sciences and Diagnostics Markets Group | \$ 2,466        | \$ 2,780        | (11%)                      |  |  |  |
| Agilent CrossLab Group                      | 2,747           | 2,656           | 3%                         |  |  |  |
| Applied Markets Group                       | 1,297           | 1,397           | (7%)                       |  |  |  |
| Agilent                                     | <u>\$ 6,510</u> | <u>\$ 6,833</u> | (5%)                       |  |  |  |

  

| <b>Non GAAP Revenue by Segment</b>          | Non-GAAP<br>(excluding Acquisitions & Divestitures) |                 |                            | Year-over-Year<br>at Constant Currency <sup>(a)</sup> |   | Current Quarter<br>Currency Impact<br><sup>(b)</sup> |
|---|---|-----------------|----------------------------|---|---|--|
|   | FY24  | FY23            | Year-over-Year<br>% Change | Year-over-Year<br>% Change                            | Percentage Point<br>Impact from<br>Currency | Current Quarter<br>Currency Impact<br><sup>(b)</sup> |
| Life Sciences and Diagnostics Markets Group | \$ 2,456  | \$ 2,773        | (11%)                      | (11%)   | —   | \$ 2   |
| Agilent CrossLab Group                      | 2,747   | 2,656           | 3%                         | 4%  | -1 ppt                                      | (4)  |
| Applied Markets Group                       | 1,297   | 1,397           | (7%)                       | (7%)  | —   | (5)  |
| Agilent (Core)                              | <u>\$ 6,500</u>                                     | <u>\$ 6,826</u> | (5%)                       | (5%)  | —   | <u>\$ (7)</u>  |

We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

<sup>(a)</sup> The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

<sup>(b)</sup> The dollar impact from the yearly currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATIONS OF REVENUE BY SEGMENT**  
**EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)**  
(in millions)  
(Unaudited)

| Year-over-Year                              |                 |                 |                            |  |  |  |
|---|-----------------|-----------------|----------------------------|--|--|--|
| <u>GAAP Revenue by Segment</u>              | GAAP            |                 |                            |  |  |  |
|   | Q1'23           | Q1'22           | Year-over-Year<br>% Change |  |  |  |
| Life Sciences and Diagnostics Markets Group | \$ 719          | \$ 670          | 7%                         |  |  |  |
| Agilent CrossLab Group                      | 652             | 648             | 1%                         |  |  |  |
| Applied Markets Group                       | 385             | 356             | 8%                         |  |  |  |
| Agilent                                     | <u>\$ 1,756</u> | <u>\$ 1,674</u> | 5%                         |  |  |  |

  

| <u>Non GAAP Revenue by Segment</u>          | Non-GAAP<br>(excluding Acquisitions & Divestitures) |                 |                            | Year-over-Year<br>at Constant Currency <sup>(a)</sup> |   | Current Quarter<br>Currency Impact<br><sup>(b)</sup> |
|---|---|-----------------|----------------------------|---|---|--|
|   | Q1'23   | Q1'22           | Year-over-Year<br>% Change | Year-over-Year<br>% Change                            | Percentage Point<br>Impact from<br>Currency | Current Quarter<br>Currency Impact<br><sup>(b)</sup> |
| Life Sciences and Diagnostics Markets Group | \$ 717  | \$ 670          | 7%                         | 11%   | -4 pts                                      | \$ (29)  |
| Agilent CrossLab Group                      | 652   | 648             | 1%                         | 7%  | -6 pts                                      | (41)   |
| Applied Markets Group                       | 385   | 356             | 8%                         | 14%   | -6 pts                                      | (19)   |
| Agilent (Core)                              | <u>\$ 1,754</u>                                     | <u>\$ 1,674</u> | 5%                         | 10%   | -5 pts                                      | <u>\$ (89)</u>                                       |

We compare the year-over-year change in revenue excluding the effect of acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

<sup>(a)</sup> The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

<sup>(b)</sup> The dollar impact from the quarterly currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATIONS OF REVENUE BY SEGMENT**  
**EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)**  
(in millions)  
(Unaudited)

| Year-over-Year                              |                 |                 |                         |  |  |  |
|---|-----------------|-----------------|-------------------------|--|--|--|
| <b>GAAP Revenue by Segment</b>              | GAAP            |                 |                         |  |  |  |
|   | Q2'23           | Q2'22           | Year-over-Year % Change |  |  |  |
| Life Sciences and Diagnostics Markets Group | \$ 726          | \$ 690          | 5%                      |  |  |  |
| Agilent CrossLab Group                      | 660             | 613             | 8%                      |  |  |  |
| Applied Markets Group                       | 331             | 304             | 9%                      |  |  |  |
| Agilent                                     | <u>\$ 1,717</u> | <u>\$ 1,607</u> | 7%                      |  |  |  |

  

| <b>Non GAAP Revenue by Segment</b>          | Non-GAAP<br>(excluding Acquisitions & Divestitures) |                 |                         | Year-over-Year<br>at Constant Currency <sup>(a)</sup> |                                       | Current Quarter<br>Currency Impact <sup>(b)</sup> |
|---|---|-----------------|-------------------------|---|---------------------------------------|---|
|   | Q2'23   | Q2'22           | Year-over-Year % Change | Year-over-Year % Change                               | Percentage Point Impact from Currency | Current Quarter Currency Impact <sup>(b)</sup>    |
| Life Sciences and Diagnostics Markets Group | \$ 723  | \$ 690          | 5%                      | 7%  | -2 pts                                | \$ (14)   |
| Agilent CrossLab Group                      | 660   | 613             | 8%                      | 11%   | -3 pts                                | (22)  |
| Applied Markets Group                       | 331   | 304             | 9%                      | 12%   | -3 pts                                | (9)   |
| Agilent (Core)                              | <u>\$ 1,714</u>                                     | <u>\$ 1,607</u> | 7%                      | 10%   | -3 pts                                | <u>\$ (45)</u>                                    |

We compare the year-over-year change in revenue excluding the effect of acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

<sup>(a)</sup> The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

<sup>(b)</sup> The dollar impact from the quarterly currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATIONS OF REVENUE BY SEGMENT**  
**EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)**  
(in millions)  
(Unaudited)

|   | Year-over-Year  |                 |                            |  |  |  |
|---|-----------------|-----------------|----------------------------|--|--|--|
| <u>GAAP Revenue by Segment</u>              | GAAP            |                 |                            |  |  |  |
|   | Q3'23           | Q3'22           | Year-over-Year<br>% Change |  |  |  |
| Life Sciences and Diagnostics Markets Group | \$ 661          | \$ 718          | (8%)                       |  |  |  |
| Agilent CrossLab Group                      | 672             | 639             | 5%                         |  |  |  |
| Applied Markets Group                       | 339             | 361             | (6%)                       |  |  |  |
| Agilent                                     | <u>\$ 1,672</u> | <u>\$ 1,718</u> | <u>(3%)</u>                |  |  |  |

  

| <u>Non GAAP Revenue by Segment</u>          | Non-GAAP<br>(excluding Acquisitions & Divestitures) |                 |                            | Year-over-Year<br>at Constant Currency <sup>(a)</sup> |   | Current Quarter<br>Currency Impact <sup>(b)</sup> |
|---|---|-----------------|----------------------------|---|---|---|
|   | Q3'23   | Q3'22           | Year-over-Year<br>% Change | Year-over-Year<br>% Change                            | Percentage Point<br>Impact from<br>Currency | Current Quarter<br>Currency Impact <sup>(b)</sup> |
| Life Sciences and Diagnostics Markets Group | \$ 659  | \$ 718          | (8%)                       | (8%)  | —   | \$ (1)  |
| Agilent CrossLab Group                      | 672   | 639             | 5%                         | 6%  | -1 ppt                                      | (5)   |
| Applied Markets Group                       | 339   | 361             | (6%)                       | (6%)  | —   | (2)   |
| Agilent (Core)                              | <u>\$ 1,670</u>                                     | <u>\$ 1,718</u> | <u>(3%)</u>                | <u>(2%)</u>   | <u>-1 ppt</u>                               | <u>\$ (8)</u>                                     |

We compare the year-over-year change in revenue excluding the effect of acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

<sup>(a)</sup> The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

<sup>(b)</sup> The dollar impact from the quarterly currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATIONS OF REVENUE BY SEGMENT**  
**EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)**  
(in millions)  
(Unaudited)

| Year-over-Year                              |   |              |                                    |   |  |   |
|---|---|--------------|------------------------------------|---|--|---|
|   | <b>GAAP</b>   |              |                                    |   |  |   |
| <b>GAAP Revenue by Segment</b>              | <b>Q4'23</b>  | <b>Q4'22</b> | <b>Year-over-Year<br/>% Change</b> |   |  |   |
| Life Sciences and Diagnostics Markets Group | \$ 674  | \$ 766       | (12%)                              |   |  |   |
| Agilent CrossLab Group                      | 672   | 663          | 1%                                 |   |  |   |
| Applied Markets Group                       | 342   | 420          | (19%)                              |   |  |   |
| Agilent                                     | \$ 1,688  | \$ 1,849     | (9%)                               |   |  |   |
|   |   |              |                                    |   |  |   |
|   | <b>Non-GAAP<br/>(excluding Acquisitions &amp; Divestitures)</b> |              |                                    | <b>Year-over-Year<br/>at Constant Currency <sup>(a)</sup></b> |  |   |
| <b>Non GAAP Revenue by Segment</b>          | <b>Q4'23</b>  | <b>Q4'22</b> | <b>Year-over-Year<br/>% Change</b> | <b>Year-over-Year<br/>% Change</b>                            | <b>Percentage Point<br/>Impact from<br/>Currency</b> | <b>Current Quarter<br/>Currency Impact<br/><sup>(b)</sup></b> |
| Life Sciences and Diagnostics Markets Group | \$ 674  | \$ 764       | (12%)                              | (13%)   | 1 ppt  | \$ 9  |
| Agilent CrossLab Group                      | 672   | 663          | 1%                                 | —   | 1 ppt  | 8   |
| Applied Markets Group                       | 342   | 420          | (19%)                              | (19%)   | —  | 3   |
| Agilent (Core)                              | \$ 1,688  | \$ 1,847     | (9%)                               | (10%)   | 1 ppt  | \$ 20   |

We compare the year-over-year change in revenue excluding the effect of acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

<sup>(a)</sup> The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

<sup>(b)</sup> The dollar impact from the quarterly currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATIONS OF REVENUE BY SEGMENT**  
**EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)**  
(in millions)  
(Unaudited)

| Year-over-Year                              |          |          |                            |  |  |  |
|---|----------|----------|----------------------------|--|--|--|
| <b>GAAP Revenue by Segment</b>              | GAAP     |          |                            |  |  |  |
|   | FY23     | FY22     | Year-over-Year<br>% Change |  |  |  |
|   | FY23     | FY22     | % Change                   |  |  |  |
| Life Sciences and Diagnostics Markets Group | \$ 2,780 | \$ 2,844 | (2%)                       |  |  |  |
| Agilent CrossLab Group                      | 2,656    | 2,563    | 4%                         |  |  |  |
| Applied Markets Group                       | 1,397    | 1,441    | (3%)                       |  |  |  |
| Agilent                                     | \$ 6,833 | \$ 6,848 | —                          |  |  |  |

  

| <b>Non GAAP Revenue by Segment</b>          | Non-GAAP<br>(excluding Acquisitions & Divestitures) |          |                            | Year-over-Year<br>at Constant Currency <sup>(a)</sup> |   | Current Quarter<br>Currency Impact <sup>(b)</sup> |
|---|---|----------|----------------------------|---|---|---|
|   | FY23  | FY22     | Year-over-Year<br>% Change | Year-over-Year<br>% Change                            | Percentage Point<br>Impact from<br>Currency | Current Quarter<br>Currency Impact <sup>(b)</sup> |
|   | FY23  | FY22     | % Change                   | % Change  | Impact from<br>Currency                     | Current Quarter<br>Currency Impact <sup>(b)</sup> |
| Life Sciences and Diagnostics Markets Group | \$ 2,773  | \$ 2,842 | (2%)                       | (1%)  | -1 ppt                                      | \$ (35)   |
| Agilent CrossLab Group                      | 2,656   | 2,563    | 4%                         | 6%  | -2 ppts                                     | (60)  |
| Applied Markets Group                       | 1,397   | 1,441    | (3%)                       | (1%)  | -2 ppts                                     | (27)  |
| Agilent (Core)                              | \$ 6,826  | \$ 6,846 | —                          | 1%  | -1 ppt                                      | \$ (122)  |

We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

<sup>(a)</sup> The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

<sup>(b)</sup> The dollar impact from the yearly currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.